Abstract
Rituximab is a chimeric murine/human monoclonal antibody that targets the CD20 antigen expressed on B lymphocytes. It is Food and Drug Administration-approved for use in pemphigus vulgaris (PV). Usual adverse effects are mild, and vasculitis has been reported very rarely. There are only three biopsy-proven case reports of rituximab-induced vasculitis in medical published literature and none in pemphigus. Here, we report a case of rituximab-induced vasculitis in a 46-year-old female with PV.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
